In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma

Gynecologic Oncology

Volumn 64, Issue 1, 1997, Pages 18-25

  Madrigal, Marilu ^a   Janicek, Mike F ^a   Sevin, Bernd Uwe ^a   Perras, James ^a   Estape, Ricardo ^a   Peñalver, Manuel ^a   Averette, Hervy E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; ONCOPROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; VIRUS PROTEIN;

ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; VIRUS ONCOGENE; WART VIRUS;

EID: 0031013016     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.4515     Document Type: Article

References (21)

1. 1. Munger, K. Host-viral gene interactions in cervical cancer, Contemp. Obstet. Gynecol., 27-37 (1995).
2. 2. Romanczuk, H., and Howley, P. M. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity, Proc. Nat. Acad. Sci. USA 89, 3159-3163 (1992).
3. 3. Storey, A., Oates, D., Banks, L., Crawford, L., and Crook, T. Antisense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16, Nucleic Acids Res. 19(15), 4109-4114 (1991).
4. 4. Steele, C., Cowsert, L. M., and Shillitoe, E. J. Effects of human papillo-mavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines, Cancer Res. 53, 2330-2337 (1993).
5. 5. Tan, T. M., and Ting, R. C. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes, Cancer Res. 55(20), 4599-4605 (1995).
6. 6. Tan, T. M., Gloss, B., Bernard, H. U., and Ting, R. C. Mechanism of translation of the bicistronic mRNA encoding human papillomavirus type 16 E6-E7 genes., J. Gen. Virol. 75(10), 2663-2670 (1994).
7. 7. Iwasaka, T., Oh-Uchida, M., Matsuo, N., Yokoyama, M., Fukuda, K., Hara, K., Fukuyama, K., Hori, K., and Sugimori, H. Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines, Gynecol. Oncol. 48, 104-109 (1993).
8. 8. Paquette, R. L., Lee, Y. Y., Wilczynski, S. P., Karmakar, A., Kizaki, M., Miller, C. W., and Koeffler, H. P. Mutations of p53 and human papillomavirus infection in cervical carcinoma, Cancer 72(4), 1272-1280 (1993).
9. 9. Scheffner, M., Munger, K., Byrne, J. C., and Howley, P. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines, Proc. Natl. Acad. Sci. USA 88, 5523-5527 (1991).
10. 10. Stacey, S. N., Eklund, C., Jordan, D., Smith, N. K., Stern, P., Dillner, J., and Arrand, J. R. Scanning the structure and antigenicity of HPV-16 E6 and E7 oncoproteins using antipeptide antibodies, Oncogene 9, 635-645 (1994).
11. 11. Wrede, D., Tidy, J. A., Crook, T., Lane, D., and Vousden, K. H. Expression of Rb and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines, Mol. Carcinogen. Commun. 4, 171-175 (1991).
12. 12. Munger, K., Scheffner, M., Huibregtse, J. M., et al. Interactions of HPV E6 and E7 with tumor suppressor gene products, Cancer Surv. 12, 197 (1992).
13. 13. Cole, S. T., and Danos, O. Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome, J. Mol. Biol. 193, 599-608 (1987).
14. 14. Czegledy, J., Bata, I., Evander, M., Gergely, L., and Wadell, G. Analysis of transforming gene regions of human papillomavirus type 16 in normal cervical smears, Arch. Gynecol. Obstet. 249, 185-189 (1991).
15. 15. Digene Diagnostics, Inc., Digene HPV Profile, Beltsville, Maryland (1994).
16. 16. Koechli, O. R., Sevin, B. U., Perras, J., Angioli, R., Steren, A., Rodriguez, M., Ganjei, P., and Averette, H. E. Growth characteristics of nonmalignant cells in the ATP cell viability assay, Oncology 51(1), 33-41 (1994).
17. 17. Sevin, B. U., Peng, Z. L., Perras, J. P., Ganjei, P., Penalver, M., and Averette, H. E. Application of an ATP bioluminescence assay in human tumor chemosensitivity testing, Gynecol. Oncol. 31, 191-204 (1988).
18. 18. Chou, T. C., and Talalay, P. Application of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents, in New avenues in developmental cancer chemotherapy (K. R. Harrap,and T. A. Connors, Eds.), Academic Press, San Diego, pp. 38-61 (1987).
19. 19. Janicek, M. F., Sevin, B. U., Nguyen, H. N., and Averette, H. E. Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines, Gynecol. Oncol. 59, 87-92 (1995).
20. 20. Janicek, M. F., Nguyen, H. N., Sevin, B. U., Unal, A. D., Scott, W., and Averette, H. E. Combination gene therapy targeting myc and p53 in endometrial cancer cell lines, Submitted for publication (1995).
21. 21. Crooke, R. M., In vitro and in vivo toxicology, in Antisense research and applications (S. T. Crooke and B. Lebleu, Eds.), CRC Press, Boca Raton, FL, pp. 471-492 (1993)